Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 8, 2014, Pages 679-685

  Aubert, C E ^a,b   Michel, P L ^a   Gillery, P ^c,d   Jaisson, S ^c,d   Fonfrede, M ^a   Morel, F ^a   Hartemann, A ^a,e   Bourron, O ^a,e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Hopital Cantonal de Fribourg   (Switzerland)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d CNRS   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Advanced glycation; Advanced glycation end products; Peripheral neuropathy; Risk factors; Type 2 diabetes

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYL GLYOXALHYDROIMIDAZOLONE 1; PENTOSIDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LYSINE; N(6)-CARBOXYMETHYLLYSINE;

ADULT; AGE; AGED; ARTICLE; BODY HEIGHT; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; GLYCOXIDATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUROPATHY DISABILITY SCORE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PERIPHERAL NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; SCORING SYSTEM; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; COMPLICATION; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHIES; FRANCE; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PREVALENCE; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SOLUBILITY; URINE;

AGED; ARTERIAL OCCLUSIVE DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MALE; MIDDLE AGED; PARIS; PERIPHERAL NERVOUS SYSTEM; PREVALENCE; RECEPTORS, IMMUNOLOGIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SOLUBILITY; WAIST CIRCUMFERENCE;

EID: 84910670601     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2529     Document Type: Article

References (26)

1. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36(2): 150-154.
2. Boulton AJ. The pathogenesis of diabetic foot problems: an overview. Diabet Med 1996; 13(Suppl 1): S12-16.
3. Carrington AL, Shaw JE, Van Schie CHM, Abbott CA, Vileikyte L, Boulton AJM. Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care 2002; 25(11): 2010-2015.
4. Dyck PJ, Dyck PJB, Klein CJ, Weigand SD. Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population-based study. Muscle Nerve 2007; 36(4): 536-541.
5. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31(3): 464-469.
6. Tapp RJ, Shaw JE, de Courten MP, Dunstan DW, Welborn TA, Zimmet PZ. Foot complications in type 2 diabetes: an Australian population-based study. Diabet Med 2003; 20(2): 105-113.
7. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000; 43(8): 957-973.
8. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004; 27(6): 1458-1486.
9. Sima AA, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia 1999; 42(7): 773-788.
10. Jaisson S, Gillery P. Evaluation of nonenzymatic posttranslational modification-derived products as biomarkers of molecular aging of proteins. Clin Chem 2010; 56(9): 1401-1412.
11. Busch M, Franke S, Rüster C, Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010; 40(8): 742-755.
12. Yang SJ, Kim S, Hwang SY, Kim TN, Choi HY, Yoo HJ, et al. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography. Atherosclerosis 2012; 220(2): 402-406.
13. Lutgers HL, Graaff R, Links TP, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care déc 2006; 29(12): 2654-2659.
14. Noordzij MJ, Mulder DJ, Oomen PHN, et al. Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type2 diabetes mellitus-a multi-centre study. Diabet Med 2012; 29(12): 1556-1561.
15. Meerwaldt R, Links TP, Graaff R, et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005; 48(8): 1637-1644.
16. Gerrits EG, Lutgers HL, Kleefstra N, et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008; 31(3): 517-521.
17. El-Mesallamy HO, Hamdy NM, Ezzat OA, Reda AM. Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot. J Investig Med 2011; 59(8): 1233-1238.
18. Witzke KA, Vinik AI, Grant LM, et al. Loss of RAGE defense: a cause of Charcot neuroarthropathy? Diabetes Care 2011; 34(7): 1617-1621.
19. Humpert PM, Papadopoulos G, Schaefer K, et al. sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm Metab Res 2007; 39(12): 899-902.
20. Boulton AJM. Management of diabetic peripheral neuropathy. Clinical Diabetes 2005; 23(1): 9-15.
21. Kumar S, Fernando DJ, Veves A, Knowles EA, Young MJ, Boulton AJ. Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration. Diabetes Res Clin Pract 1991; 13(1-2): 63-67.
22. International Working Group on the Diabetic Foot, International Consensus on the Diabetic Foot. Prevention: Risk categorization system. 1999.
23. Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002; 19(5): 377-384.
24. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114(6): 597-605.
25. Tan KCB, Shiu SWM, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49(11): 2756-2762.
26. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106(22): 2827-2835.